Literature DB >> 2474235

Central nervous system toxicity of interferons and other cytokines.

V Bocci1.   

Abstract

Prolonged administration of interferons, interleukins and tumor necrosis factor are accompanied by a range of toxic effects of which central nervous system toxicity may be an important dose-limiting factor. While symptoms are widely reported, practically nothing is known about mechanisms of action. This review attempts to distinguish between a direct effect of cytokines upon circumventricular organs and an indirect effect mediated by factors released by endothelial-glial cells of the blood-brain barrier normally impermeable to cytokines. In order to reduce the toxicity of biological response modifiers the definition of the minimum effective dose, the use of the lymphatic route and the observance of the chronobiological rules may help to improve the therapeutic index of these hormone-like compounds. It appears however, that the relationship between cytokine: dose: route: schedule: timing on one side and efficacy: toxicity on the other is complex, and so far no general rule has clearly emerged so that at the moment it appears necessary to find out the optimal therapeutic index for each particular disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2474235

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  13 in total

1.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 2.  Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Does an unorthodox route improve the therapeutic index of interferon?

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  Interleukin-2 lengthens extrajunctional acetylcholine receptor channel open time in mammalian muscle cells.

Authors:  P Lorenzon; F Ruzzier; C G Caratsch; A Giovannelli; F Velotti; A Santoni; F Eusebi
Journal:  Pflugers Arch       Date:  1991-10       Impact factor: 3.657

4.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 5.  Transgenic models for cytokine-induced neurological disease.

Authors:  Iain L Campbell; Markus J Hofer; Axel Pagenstecher
Journal:  Biochim Biophys Acta       Date:  2009-10-14

6.  Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; D Desprès; J Aman; P Trautman; H Tilg; G Rudolf; H Hüttmann; J Obermeier; M Herold
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

7.  Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.

Authors:  A Pace; A Pietrangeli; L Bove; M Rosselli; M Lopez; B Jandolo
Journal:  Ital J Neurol Sci       Date:  1994-10

Review 8.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

9.  Ocular pseudo-myasthenic reaction induced by interferon in an AIDS patient.

Authors:  R R Riedel; A Schmitt; A Hartmann
Journal:  Klin Wochenschr       Date:  1991-12-11

10.  The in vivo effect of lipopolysaccharide on the spontaneous release of transmitter from motor nerve terminals.

Authors:  S H Liu; T J Sheu; R H Lin; S Y Lin-Shiau
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.